The efficacy of gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia was evaluated in 26 individuals over a mean period of 16 months. In the untreated state both disorders are associated with a high frequency of coronary heart disease. In the former, gemfibrozil with a bile acid sequestrant reduced plasma cholesterol by 32%, an incremental decrease of 17% compared with sequestrant therapy alone. In type III, plasma cholesterol was reduced by 40% and plasma triglyceride by 70%, while high-density lipoprotein cholesterol increased by 45%. In none of the patients studied did clinical or biochemical side effects occur.
Introduction
Lipid-lowering drugs, like antihypertensives, are prescribed long-term for correction of asymptomatic disorders with a view to reduction ofthe risk offuture disease. Such drugs are necessarily judged by rigorous criteria of safety, effectiveness and cost. Gemfibrozil, recently introduced for general use in the UK as a lipid-lowering agent, is a fibric acid derivative that reduces triglyceride and cholesterol levels by lowering plasma very-low-density and low-density lipoproteins (VLDL and LDL); it also increases high-density lipoprotein (HDL) cholesterol'-3. In a 5-year large-scale randomized placebo-controlled trial, few untoward effects were evident4.
We have assessed the metabolic effects ofgemfibrozil in two primary hyperlipidaemic states associated with a high risk of cardiovascular complications5. Remnant (type III) hyperlipoproteinaemia responds to other drugs of the fibric acid group6, and we have studied its response to gemfibrozil in view of the low frequency of subjective and other untoward effects of this drug"4. We have also used gemfibrozil in a twodrug regimen in the management of the common problem of resistant heterozygous familial hypercholesterolaemia, i.e. in patients in whom previous monotherapy or drug combinations together with a lipid-lowering diet had failed to achieve acceptable control of the hyperlipidaemia. We report here on our experience with the drug in 26 patients, followed for up to three years. 0141-0768/88/ 050274-03/$02.00/0
Patients and methods All patients attended the St Thomas' Hospital lipid clinic and each received gemfibrozil (600 mg twice daily) for a period of 3 to 36 months (mean 16 months). Thirteen patients with remnant hyperlipoproteinaemia (9 males, 4 females) and 13 with resistant familial hypercholesterolaemia (11 males, 2 females) were studied. In the latter group serum cholesterol levels had remained persistently above 7.8 mmol/l despite treatment with a bile acid sequestrant drug in maximal tolerated dosage (4-10 sachets per day), either singly or in combination with other drugs, for periods of 6 months to 7 years. Three familial hypercholesterolaemic patients were receiving the bile sequestrant drug colestipol, and 10 were treated with cholestyramine. Five ofthese were also receiving probucol 0.5 g twice daily, and 4 were treated with nicofuranose (Bradilan) 1 g three times daily in addition to their resin medication. All patients studied were taking a fat-modified lipid-lowering diet7. Two or more baseline measurements in familial hypercholesterolaemia were made during the previous sequestrant or two-drug therapy and lipid-lowering diet, not less than 3 months after the last change in medication or in dosage. In remnant hyperlipoproteinaemia they were made after stabilization (2-3 months) on a lipid-lowering diet. During the drug trial body weight did not change by more than ±2 kg.
The diagnosis of familial hypercholesterolaemia was based upon a serum cholesterol greater than 7.8 mmol/1, due to elevation of LDL cholesterol, the presence of tendon xanthomas in an index patient or in a first-degree relative and/or hypercholesterolaemia in 2 or more first-degree relatives. Type III hyperlipoproteinaemia was defined as the presence of serum cholesterol greater than 7.3 mmol/l and serum triglyceride greater than 3 mmol/l due to elevation of VLDL and intermediate density lipoproteins together with a molar ratio of cholesterol: triglyceride in VLDL of >0.6. Laboratory methods Cholesterol and triglyceride were measured in samples obtained without venous stasis, after an overnight 14-hour fast, employing automated enzymatic methods based on Boehringer-Mannheim and Wako (GmbH) reagents respectively, using the Cobas Bio centrifugal analyser. HDL cholesterol was determined using heparin/2M manganese precipitation8.
Results
In patients with type III hyperlipoproteinaemia a 40% reduction in serum cholesterol, 70% reduction in triglyceride and a concomitant increase in HDL cholesterol of 45% were achieved (Table 1) . Of the 13 patients with familial hypercholesterolaemia, 10 showed a marked response; 3 were refractory to this additional medication, their serum cholesterol levels remaining above 10 mmol/l. Considering all 13 patients, a 17% incremental reduction in serum cholesterol and a 50% reduction in triglyceride were observed on adding gemfibrozil to the pre-existing cholestyramine or colestipol therapy ( Table 2 ). Excluding the 3 non-responders, a cholesterol reduction of 26% with a 61% reduction in triglycerides and a 27% increase in HDL were achieved (Table 3 ). In none of the 26 patients did any clinical or biochemical side effects develop.
Discussion
Gemfibrozil appears to be a satisfactory treatment for remnant (type III) hyperlipoproteinaemia. The response observed in this series of 13 patients was better than that documented for either clofibrate or nicotinic acid9. In familial hypercholesterolaemia, gemfibrozil showed a pronounced additive interaction with bile acid sequestrant drugs. It is interesting that a combination of gemfibrozil and sequestrant was more effective than that observed in a previous report in which cholestyramine and clofibrate were used'0. In view of the possibility that sequestrant drugs may interfere with the absorption of fibrate derivatives, it is recommended that gemfibrozil should be administered before meals and cholestyramine or colestipol after meals. There is strong evidence from controlled trials, considered singly" or together'2, that the extent of reduction of the incidence of coronary heart disease is directly related to the magnitude of serum cholesterol reduction. This is in conformity with the epidemiological relation between serum cholesterol and coronary heart disease mortality, which is evident over a wide range of serum cholesterol levels'3. These considerations justify the goal of seeking therapeutic measures that maximize the reduction of elevated serum cholesterol levels, particularly in disorders such as familial hypercholesterolaemia and remnant hyperlipoproteinaemia (type III) that are strongly associated with atherosclerosis. 
